Home » Newsletters » BioWorld Asia

BioWorld Asia

July 19, 2000

View Archived Issues

Drugs For Sleep Disorders Could Follow Circadian Rhythm Finding

Zeltia Share Issue Brings In $172M On Madrid Exchange

EU Commissioners Determined To Resolve Biotech Standstill

Alizyme Plans To Raise #21M Through Public, Private Means

Other News To Note

Genomatix Completes First Pass At Promoter Sequence Analysis

French Government Launches Fund To Help Biotech Start-Ups

KS Biomedix Taking Sheep Antibody Into Human Trials

Transgene Selects 2 HGS Genes For Cardiovascular Applications

RiboTargets Gets Boost With #6M Second-Round Financing

Xenova Raises #10M In Units Offering In 'Improving' Market

French Government Confirms Its Stand On Gene Patenting

Challenges Pending For New Biotechnology Patent Rules

Biovector Plans To Move Flu Vaccine Into Phase III Trials

IBT Forced To Restructure Due To Shareholder Pressure

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....